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AbstrACt
Introduction Medically unexplained symptoms (MUS) are 
common in primary-care and secondary-care settings. 
Persistent symptoms of MUS are associated with a variety 
of poor outcomes including increased disability, poor 
quality of life and high healthcare costs. The aim of this 
systematic review is to review the relevant literature to 
determine the prevalence of MUS in patients who are high 
users of healthcare and/or who accrue high healthcare 
costs.
Methods and analysis This review will include studies 
with cases that are either high users of general healthcare 
or are patients who accrue high healthcare costs, aged 
≥18 years and where a recognised measure of MUS, 
either a standardised clinical interview or questionnaire, 
was employed. The following citation databases MEDLINE, 
PsycINFO, EMBASE, CINAHL, PROSPERO and the Cochrane 
library will be systematically searched from inception to 
30 June 2018. The Cochrane library was included because 
of the significant proportion of non-observational studies 
currently published in the database. The prevalence of 
MUS and associated disorders along with the costs or use 
of healthcare associated with the presence of MUS will be 
estimated with 95% CI. If possible, study results will be 
pooled into a meta-analysis. However, if heterogeneity is 
high, data analysis will be presented descriptively.
Ethics and dissemination Ethical approval is not 
required for this systematic review since only data from 
existing studies will be used. Results of this review will be 
disseminated in peer-reviewed publications and at national 
and international conferences.
PrOsPErO registration number CRD42018100388
IntrOduCtIOn
Medically unexplained symptoms (MUS) 
is a general term which refers to physical 
symptoms that cannot be fully explained by 
observable pathology or known/recognised 
pathological mechanisms. Such symptoms 
can affect any part of the body and can range 
from minor occasional problems to severe 
and persistent symptoms resulting in func-
tionally impaired states. At the more severe 
end, the MUS spectrum includes syndromes 
comprising multiple, chronic and disabling 
MUS.
One of the most common definitions of 
MUS is where a patient experiences physical 
symptoms ‘whereby any disease or problem 
with the body cannot be found that would 
otherwise account for the symptoms’.1 
However, there is no completely satisfactory 
definition for MUS, as the area is concep-
tually and diagnostically challenging. The 
preferred, recent term is persistent physical 
symptoms.2 Terms other than MUS have 
often been used, such as abridged somatisa-
tion disorder or multisomatoform disorder. 
These terms have predominantly been used 
for research purposes, to capture patients 
with moderate MUS, who may not meet the 
psychiatric diagnostic criteria.3
It is estimated that MUS accounts for 
approximately 20% of new consultations 
in primary care,4 5 52% of new referrals in 
secondary care6 and 20%–25% of all frequent 
attenders at medical clinics.7 8 Patients with 
MUS are commonly referred for multiple 
investigations and assessments with little 
strengths and limitations of this study
 ► To reduce bias, this review is not restricted to the 
English language or by publication date.
 ► A wide range of medical databases and study types 
will be used to identify potential papers for inclusion.
 ► A broad search strategy with a wide spectrum of 
search terms, including healthcare cost/utilisation, 
frequent attenders,  Medically unexplained symp-
toms and healthcare settings, will be used.
 ► Study selection, data extraction and quality as-
sessment will be conducted by two reviewers 
independently.
 ► We aim to conduct a meta-analysis. However, if 
sufficient number of studies are not available or 
where there is high heterogeneity between studies, 
a narrative summary of the included studies will be 
presented in the final review.
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benefit, so are needlessly costly for healthcare systems9–11 
and account for approximately 10% of the total National 
Health Service (NHS) expenditure for the working-age 
adult population in England. The annual cost attributable 
to MUS due to lost productivity and decreased quality of 
life is over £14 billion to the UK economy.12 However, 
there is no satisfactory review of the available literature to 
support such estimations.
The overall purpose of this systematic review is to deter-
mine the prevalence of MUS in patients who are high 
users of healthcare and/or who accrue high healthcare 
costs and the magnitude of healthcare or associated costs.
Aims
This systematic review will aim to:
 ► Determine the prevalence of MUS in adults aged ≥18 
years who are high users of healthcare or ‘high-cost’ 
patients (those who accrue high heathcare costs).
 ► Determine the magnitude of the cost of use of health-
care associated with the presence of MUS among 
adults who are high users of healthcare.
MEthOds And dEsIgn
Population
This review will include studies where cases are adults 
who are high users of general healthcare or have high 
general healthcare costs, and have MUS. We will include 
‘patients who accrue high healthcare costs’, ‘high users’, 
‘distressed high users or users of care’, ‘frequent attenders 
in primary care’, ‘frequent attenders at the emergency 
department’.
Existing strings from databases such as the Cochrane 
database will be searched for additional search terms as 
appropriate. All cases will be adults aged 18 years or more. 
In studies where a proportion of participants is less than 
18 years old, the mean or median age (in years) and a 
description of the distribution (SD, range or IQR range) 
will be provided. If these are not reported, the authors 
may be contacted to provide raw data for these to be 
calculated.
In all studies, a recognised measure of the presence of 
MUS should have been used. This could involve using 
any of the following: a standardised research inter-
view (eg, the Structured Clinical Interview for Mental 
Disorders13 14 to generate a diagnosis of a somatoform 
disorder according to Diagnostic and Statistical Manual 
of Mental Disorders (DSM)-III15, DSM-IV-R16, DSM 
V17, International Classification of Diseases (ICD)-918, 
ICD-1019 or other relevant diagnostic systems; a clinical 
assessment leading to a clinical diagnosis of a somato-
form disorder according to any of the above diagnostic 
systems; a validated scale for the assessment of MUS, 
such as the screening for somatoform disorders,20 the 
Bradford somaticinventory,21 or component subscales of 
validated standardised instruments for the assessment of 
general psychopathology or general health status, such 
as the Patient Health Questionnaire-15 22 or an assess-
ment which generated a recognised symptom grouping 
of MUS developed for research purposes (eg, abridged 
somatisation disorder,23 multisomatoform disorder,24 
bodily distress disorde25 and complex somatic symptom 
disorder.26 Studies focusing on high use of mental health 
services, or specific medical sub-specialties, for example, 
oncology or obstetrics, will be excluded.
study design
This systematic review will consider observational studies 
including:
 ► Cohort studies – retrospective and prospective.
 ► Case–control and nested case-control.
 ► Cross-sectional studies.
Included studies will be published in either peer-re-
viewed scientific journals or Cochrane libraries. Single 
case studies and randomised controlled trials will be 
excluded.
search strategy
Search
An optimal search strategy has been developed to retrieve 
relevant articles which focus on the following key terms: 
medically unexplained symptoms (and all the associated 
diagnoses and research terms), high cost of healthcare, 
high healthcare use, frequent attenders, primary care, 
secondary care and emergency department. A detailed 
search strategy in Medline can be found in online supple-
mentary appendix 1. The following citation databases 
Medline, PsycINFO, Embase, CINAHL, PROSPERO and 
Cochrane library will be searched from inception tol 31 
December 2018. The reference lists of any recent review 
articles and from any other eligible manuscript identified 
by the above search will be hand-searched. There will be 
no language restriction, if studies in a language other 
than English are included in the review. Internet sites 
such as google translate may be used to translate blocks of 
texts from various languages into English. Furthermore, 
international colleagues/students from the Universi-
ties of Birmingham, Leeds and Manchester can provide 
support in translating non-English articles. Additionally, 
authors of non-English articles may be requested to assist 
with data translation.
Preparing for eligibility screening
Before the screening can commence, search results iden-
tified by the outlined databases will be assembled into 
a library and organised by database using the Endnote 
reference management tool. Duplicates will be identified 
and removed at this stage.
study selection
Two reviewers will independently screen and identify 
studies by reading titles and abstracts. Both reviewers 
will then select articles for full-text screening and inde-
pendently apply eligibility criteria to select the appro-
priate articles for the review. Any disagreement over the 
eligibility of any study will be resolved through discus-
sion with a third reviewer. An inclusion criteria checklist 
(table 1) has been developed based on study eligibility 
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criteria to ensure that studies are interpreted and clas-
sified appropriately. A Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA-P) flow 
diagram will be provided to describe the included and 
excluded studies along with the reasons for exclusion. 
This review will be conducted according to the PRISMA-P 
reporting guidelines.27
Quality assessment
Two reviewers will carry out the quality assessment of 
each selected article independently to reduce bias. Any 
difference in opinion will be resolved by further discus-
sion/consensus or by involving a third reviewer. Study 
quality will be assessed focusing on sampling strategy, 
validated method to establish outcome, attrition and 
analytical method employed. All selected articles will be 
judged using a modified form adapted from the Otta-
wa-Newcastle Scale ,28 to assess the quality of the cohort, 
case–control and cross-sectional studies. Online supple-
mentary appendix 2 shows the stages and domains of 
this modified tool. Risk of bias will be presented in accor-
dance with the Cochrane Collaboration recommenda-
tions.29 Risk of bias will not be displayed as a composite 
score; instead a risk of bias of ‘yes’ indicating high risk, 
‘no’, low risk and ‘unclear’ will be provided to assess 
each domain. A narrative summary of the quality for 
each study will be provided in a table. A critical appraisal 
of the study quality describing the impact of the quality 
of each study on the results will be discussed. A sensi-
tivity analysis will be conducted to assess the effect of 
including or excluding poor quality studies on the main 
findings.
data extraction
Two reviewers will independently screen and identify 
studies by reading titles and abstracts. Both reviewers 
will then select articles for full-text screening and inde-
pendently apply eligibility criteria to select the appro-
priate articles for the review. Any disagreement over the 
eligibility of a study will be resolved through discussions 
with a third reviewer. Finally, both reviewers will inde-
pendently extract data. For missing data, authors will be 
contacted for clarification. An Excel spreadsheet will be 
used to manage data extraction. A data extraction form 
(online supplementary appendix 3) will be designed 
based on the Hayden et al framework.30 This form will 
be developed iteratively and pilot-tested on known 
papers independently by two reviewers. The form will be 
designed to focus on population, comparator, outcome 
and study design.
Outcomes
The outcomes of this review will be categorised as follows:
 ► Primary outcome: prevalence of MUS.
 ► Secondary outcome: magnitude of cost or use of 
healthcare associated with the presence of MUS.
data analysis and synthesis
The outcomes of interest are the prevalence of MUS and 
cost or use of healthcare associated with the presence of:
1. MUS in patients who accrue high healthcare costs/
high use populations alone.
2. MUS in patients who accrue high healthcare costs/
high use populations in comparison with a relevant 
population (eg, general patient population or low 
cost/low use population).
Prevalence rates and standard errors will be extracted 
or calculated from the available data. If appropriate, 
cohort, case–control and cross-sectional studies will be 
grouped separately and pooled estimates of the preva-
lence rates with 95% CI will be calculated using STATA 
V.13.1 (STATA Corp). The analysis of the magnitude of 
healthcare utilisation and costs will be reported based on 
the definition of high users or patients who accrue high 
healthcare costs described by the included studies. To 
determine the cost or use of healthcare associated with 
the presence of MUS, the difference between groups 
(eg, cost/use of healthcare associated with MUS versus 
other relevant mental or physical conditions) will be 
extracted, where possible. Standardised mean difference 
with accompanying 95% CI and median OR of costs or 
healthcare utilisation will be extracted or calculated from 
the data provided. For studies reporting implementation 
of an intervention, changes in costs and healthcare utili-
sation before and after the intervention will be extracted 
and reported where available. Subgroup analyses of the 
outcome data may be performed if studies report, for 
example, clinical diagnosis of MUS based on ICD or DSM 
versus symptoms of MUS, setting (primary care, emer-
gency department and secondary physical healthcare) 
or by age group. This will allow the prevalence of MUS, 
Table 1 Review eligibility criteria checklist
Study design
Cohort studies (retrospective and 
prospective)
Case–control and nested case–control 
studies
Cross-sectional studies
Study 
characteristics
Full articles
Reference lists of any recent review article
Eligible manuscript identified by the 
database search
Participants Adult aged ≥18 years
High user of healthcare
Accrue high healthcare costs
Presence of  Medically unexplained 
symptoms (MUS)
Comparator Non-high cost and non-high users of 
healthcare
Outcome Prevalence of MUS
Patient characteristics and context 
associated with high service usage/costs 
among patients with MUS
Magnitude of cost or use of healthcare 
associated with the presence of MUS
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costs and healthcare utilisation associated with MUS to be 
compared across these groups. Depending on the level 
of heterogeneity both fixed and random effect models 
will be used as summary effect measures. To assess the 
robustness of the meta-analysis and interpretation of the 
pooled results, the quality criteria of the studies entered 
in the meta-analysis will be considered. Therefore, sepa-
rate sensitivity analyses may be conducted with at least the 
following assumptions: representative sampling strategy, 
adequate response rate and studies using both valid and 
standardised assessment and clinical interview to ascer-
tain somatoform disorders/MUS. The level of heteroge-
neity across studies will be assessed using the Cochrane 
Q-test and the I2- statistical test with 95% CI. Publica-
tion bias and small sample bias will be assessed using the 
inverted funnel plot technique and the Egger statistics. 
The Grading of Recommendations Assessment, Develop-
ment and Evaluation framework will be used to assess the 
quality of evidence for each outcome of interest described 
above across studies. Furthermore, inconsistency/impre-
cision, risk of bias including publication bias and appli-
cability of the results based on the study population will 
also be rated when making judgement about the quality 
of evidence presented in the included studies.31 If heter-
ogeneity is high between studies, a narrative summary of 
the outcome of the selected studies will be presented in 
the final review.
Patient and public involvement statement
Patients and the public were not invited to contribute to 
the writing or editing of this systematic review protocol. 
The research question of this review was informed by the 
lack of relevant literature examining the prevalence of 
patients with MUS who are high users of healthcare or 
who accrue high healthcare costs.
dIsCussIOn
This systematic review will aim to identify and present an 
in-depth synthesis of the best available evidence describing 
the prevalence of MUS in patients who are high users of 
healthcare and/or who accrue high healthcare costs. 
Strength and limitations identified in the literature will 
be highlighted and described in the review. Strength of 
observational data include large sample sizes, the poten-
tial to observe extended follow-up, frequency of atten-
dance and healthcare cost associated with MUS likely to 
be representative of the population a risk. Limitations may 
include quality of the data extracted which may be inad-
equate to allow data to be combined in a meta-analysis. 
To overcome this problem, a narrative summary of the 
findings will be presented. The search criteria, keywords 
and Medical Subject Headings terms were reviewed and 
refined with the support of an experienced librarian. The 
team identified the most appropriate medical database(s) 
based on the review question. Two reviewers will conduct 
data extraction and screening independently employing 
a data extraction form which has been reviewed and 
pretested. Additionally, this review is not limited to the 
English language and study date, and relevant papers will 
be translated to English for assessment. To the best of 
our knowledge, no existing review addresses our research 
question. However, if a review addressing a similar ques-
tion  is published, it will be incorporated in this review 
and, if feasible , added to the meta-analysis.
Implications of results
This systematic review will provide a reliable estimate of the 
prevalence of MUS in adults aged ≥18 years who are high 
users of healthcare services and/or accrue high health-
care costs. Furthermore, an updated and quantifiable esti-
mate of the costs attributed to the presence of MUS will 
be presented if sufficient evidence is available. One of the 
main premises of delivering psychological treatments for 
MUS is that such interventions may reduce healthcare costs 
in addition to improving patient outcomes. This review will 
inform policy makers, clinicians and researchers of the costs 
related to MUS in ‘high users of healthcare’, enabling more 
targeted interventions to be developed. Such interventions 
may focus on patients with MUS but, in addition, address 
factors related to healthcare use, and be of sufficient inten-
sity to impact on healthcare behaviour. Additionally, the 
systematic search and the evidence gathered may inform 
future policy directions by quantifying the problem more 
accurately than has been done before and highlighting the 
degree to which limited healthcare resources are being 
used effectively for a vulnerable and needy group of people.
Author affiliations
1School of Psychology, College of Life and Environmental Sciences, University of 
Birmingham, Edgbaston, UK
2Research and Innovation, Birmingham and Solihull Mental Health NHS Foundation 
Trust, The Barberry, Research and Innovation, Edgbaston, Birmingham, West 
Midlands, United Kingdom
3Division of Psychological and Social Medicine, Leeds Institute of Health Sciences, 
School of Medicine, University of Leeds, Leeds, UK
4Division of Nursing, Social Work and Midwifery, School of Health Sciences, 
Manchester Academic Health Science Centre, The University of Manchester, 
Manchester, UK
Contributors FJ and OCL developed the search strategy. FJ drafted the manuscript 
and registered the protocol. EG and AB were involved in the design of the review 
and provided continuous feedback on the manuscript. FJ will be first reviewer and 
OCL will be second reviewer. All authors read and approved the manuscript.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors. 
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer-reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Fink P, Fritzsche K, Söllner W, et al. Medically Unexplained 
Symptoms, Somatisation and Bodily Distress: Developing Better 
 o
n
 16 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027922 on 2 July 2019. Downloaded from 
5Jadhakhan F, et al. BMJ Open 2019;9:e027922. doi:10.1136/bmjopen-2018-027922
Open access
Clinical Services. Cambridge: Cambridge University Press, 
2011:217–35.
 2. Marks EM, Hunter MS. Medically Unexplained Symptoms: an 
acceptable term? Br J Pain 2015;9:109–14.
 3. Kleinstäuber M, Witthöft M, Steffanowski A, et al. Pharmacological 
interventions for somatoform disorders in adults. Cochrane Database 
Syst Rev 2014;7:CD010628.
 4. Bridges K Goldberg D. Somatic presentation of depressive illness in 
primary care. JR Coll Gen Pract Occas 1987;36:9–11.
 5. Knapp M, McDaid D, Parsonage M. Mental health promotion and 
mental illness prevention: the economic case: Personal Social 
Services Research Unit: London School of Economics and Political 
Sciences, 2011.
 6. Nimnuan C, Rabe-Hesketh S, Wessely S, et al. How many functional 
somatic syndromes? J Psychosom Res 2001;51:549–57.
 7. Fink P. The use of hospitalizations by persistent somatizing patients. 
Psychol Med 1992;22:173–80.
 8. Reid S, Wessely S, Crayford T, et al. Medically unexplained 
symptoms in frequent attenders of secondary health care: 
retrospective cohort study. BMJ 2001;322:767–9.
 9. Reid S, Wessely S, Crayford T, et al. Frequent attenders with 
medically unexplained symptoms: service use and costs in 
secondary care. Br J Psychiatry 2002;180:248–53.
 10. Kroenke K, Mangelsdorff AD. Common symptoms in ambulatory 
care: incidence, evaluation, therapy, and outcome. Am J Med 
1989;86:262–6.
 11. McGorm K, Burton C, Weller D, et al. Patients repeatedly referred 
to secondary care with symptoms unexplained by organic disease: 
prevalence, characteristics and referral pattern. Fam Pract 
2010;27:479–86.
 12. Bermingham SL, Cohen A, Hague J, et al. The cost of somatisation 
among the working-age population in England for the year 2008-
2009. Ment Health Fam Med 2010;7:71–84.
 13. First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for 
DSM-IV-TR axis disorders, research version, patient edition (SCID-
I/P). New York: Biometrics Research, New York State Psychiatric 
Institute, 2002.
 14. Spitzer RL, Williams JBW, Gibbon M, et al. User’s guide for the 
structured clinical interview for DSM-III-R: SCID. Arlington, VA, USA: 
American Psychiatric Association, 1990.
 15. American Psychiatric Association. Diagnostic and Statistical Manual 
of Mental Disorders. 3rd ed. Washington DC: American Psychiatric 
Association, 1980.
 16. American Psychiatric Association. Diagnostic and statistical manual 
of mental disorders. 4th ed. Washington DC: American Psychiatric 
Association, 2000.
 17. American Psychiatric Association. Diagnostic and statistical manual 
of mental disorders. 5th ed. Arlington, VA, USA: American Psychiatric 
Association, 2013.
 18. World Health Organisation. International Classification of Diseases. 
9th ed. Atlanta, GA: Centres for Disease Control and Prevention, 
1975.
 19. World Health Organisation. International Statistical Classification 
of Diseases and Related Health Problems. 10th Revision. WHO, 
Geneva: (ICD-10), 1992.
 20. Rief W, Hiller W, Heuser J. SOMS - Das Screening für Somatoforme 
Störungen (Manual zum Fragebogen) Bern. Hans Huber 1997.
 21. Mumford DB, Bavington JT, Bhatnagar KS, et al. The Bradford 
Somatic Inventory. A multi-ethnic inventory of somatic symptoms 
reported by anxious and depressed patients in Britain and the Indo-
Pakistan subcontinent. Br J Psychiatry 1991;158:379–86.
 22. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a 
new measure for evaluating the severity of somatic symptoms. 
Psychosom Med 2002;64:258–66.
 23. Escobar JI, Waitzkin H, Silver RC, et al. Abridged somatization: a 
study in primary care. Psychosom Med 1998;60:466–72.
 24. Kroenke K, Spitzer RL, deGruy FV, et al. Multisomatoform 
disorder. An alternative to undifferentiated somatoform disorder 
for the somatizing patient in primary care. Arch Gen Psychiatry 
1997;54:352–8.
 25. Fink P, Toft T, Hansen MS, et al. Symptoms and syndromes of bodily 
distress: an exploratory study of 978 internal medical, neurological, 
and primary care patients. Psychosom Med 2007;69:30–9.
 26. Dimsdale J, Creed F. DSM-V Workgroup on Somatic Symptom 
Disorders. The proposed diagnosis of somatic symptom disorders 
in DSM-V to replace somatoform disorders in DSM-IV--a preliminary 
report. J Psychosom Res 2009;66:473–6.
 27. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for 
systematic review and meta-analysis protocols (PRISMA-P) 2015 
statement. Syst Rev 2015;4:1:1.
 28. Hartling L, Milne A, Hamm MP, et al. Testing the Newcastle Ottawa 
Scale showed low reliability between individual reviewers. J Clin 
Epidemiol 2013;66:982–93.
 29. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane 
Collaboration's tool for assessing risk of bias in randomised trials. 
BMJ 2011;343:d5928–9.
 30. Hayden JA, Côté P, Bombardier C. Evaluation of the Quality 
of Prognosis Studies in Systematic Reviews. Ann Intern Med 
2006;144:427–37.
 31. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. 
Introduction-GRADE evidence profiles and summary of findings 
tables. J Clin Epidemiol 2011;64:383–94.
 o
n
 16 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027922 on 2 July 2019. Downloaded from 
